{
  "id": 7491494,
  "title": "Thalia Therapeutics advances RNA therapy programs",
  "url": "https://urgent.news/2026/09/15/thalia-therapeutics-advances-rna-therapy-programs",
  "topic": "science",
  "section": "Science",
  "published": "2026-09-15T06:31:16.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/thalia-therapeutics-advances-rna-therapy-programs-93CH-4900854"
  },
  "original_language": "en",
  "account": null,
  "summary": "Thalia Therapeutics plc has reported significant progress in its RNA-based therapeutics development programs, including the continuation of a Phase 1 dose-escalation clinical trial for miRisten in patients with relapsed or refractory Acute Myeloid Leukemia (AML). The therapy, which inhibits microRNA-126 to target leukemia stem cells, is being developed for AML, a condition that affects over 22,000 new U.S. patients annually. Additionally, Thalia has commenced preclinical development of THAT-002, a bispecific siRNA cardiovascular program targeting PCSK9 and lipoprotein(a), with plans for IND-enabling non-human primate studies in early 2027. The company has also appointed Luke Cairns as Chief Financial Officer and completed a rebranding and acquisition in July 2026, along with a £2.75 million fundraise. Thalia will provide an update on its interim results for the six months ended June 30, 2026 on September 30.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}